Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated (NASDAQ: ARAY) generates a steady flow of news related to radiation oncology, product innovation, clinical collaborations and corporate strategy. As a developer and manufacturer of radiation therapy systems such as the CyberKnife System and the Radixact Treatment Delivery System, the company regularly issues updates on technology launches, clinical milestones and organizational changes that are relevant to investors, clinicians and other stakeholders following ARAY stock.
News about Accuray often highlights advances in its radiation therapy portfolio. Recent announcements have included the introduction of the Accuray Stellar Solution, a configuration of the Radixact system initially for the U.S. market, designed to support adaptive radiotherapy and multiple delivery modalities. The company also reports on collaborations, such as a memorandum of understanding with the University of Wisconsin School of Medicine and Public Health to advance online adaptive radiotherapy on its helical radiation treatment delivery platform.
Corporate and financial developments are another key focus of Accuray’s news flow. Press releases and related SEC filings cover quarterly and annual financial results, guidance, non-GAAP measures such as adjusted EBITDA, and details of a comprehensive strategic, operational and organizational transformation plan. These communications describe initiatives such as streamlining the commercial structure, centralizing core functions, outsourcing selected non-core activities, and workforce reductions, along with associated restructuring charges and expected effects on operating profitability.
Governance and capital structure updates also appear in the company’s news. Examples include leadership changes, board appointments, equity incentive plans, and financing agreement amendments that involve warrants to purchase common stock. Clinical and market expansion stories, such as the first CyberKnife S7 System treatments in Melbourne, Australia through a collaboration with 5D Clinics and Icon Group, illustrate how Accuray’s technology is being deployed in new locations and settings.
This ARAY news page brings together these types of announcements in one place, allowing readers to review product launches, clinical collaborations, financial disclosures and transformation updates over time. For anyone researching Accuray’s business direction, technology focus or corporate actions, the news feed offers a structured view of the company’s public communications.
Accuray (NASDAQ: ARAY) announced it will host an analyst and investor event during the American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco on September 29, 2025. The hybrid event, starting at 1:30 PM PT, will feature global thought leaders discussing adaptive radiotherapy in radiation medicine.
The presentation will cover key topics including the adaptive radiotherapy spectrum, programmatic vision, practice integration, workflow realities, and motion management from a global perspective. Both in-person and virtual attendees must register by September 25, 2025.
Accuray (NASDAQ: ARAY) reported its Q4 and fiscal 2025 results with mixed performance. Q4 revenue decreased 5% to $127.5 million, while full-year revenue grew 3% to $458.5 million. The company posted Q4 net income of $1.1 million compared to $3.4 million in the prior year, while recording a full-year net loss of $1.6 million, improved from a $15.5 million loss in FY24.
Service revenue showed strength with a 4% increase in both Q4 and full-year results. The company successfully completed a debt refinancing and maintained a book-to-bill ratio of 1.2. For FY26, Accuray projects revenue between $471-485 million and adjusted EBITDA of $31-35 million.
Accuray (NASDAQ: ARAY) has scheduled its fourth quarter fiscal 2025 financial results conference call for August 13, 2025, at 1:30 p.m. PT/4:30 p.m. ET. The company will provide financial results for the quarter ended June 30, 2025.
Investors can access the call through U.S. dial-in (1-888-999-5318) or international dial-in (1-848-280-6460). A replay will be available for one week after the call. Additionally, a live webcast will be accessible through the company's Investor Relations website at investors.accuray.com, with the replay available until Q1 fiscal 2026 results.
Accuray (NASDAQ: ARAY) announced the first patient treatments with the CyberKnife® System in Austria at the CyberKnife® Center Salzburg. The center utilized Accuray's CyberComm™ technology to commission their latest-generation CyberKnife S7™ System, reducing commissioning time by approximately 50%. The system delivers ultra-hypofractionated radiation therapy in just 1-5 outpatient sessions, compared to conventional 30-40 sessions, with sub-millimeter accuracy.
This installation is particularly significant as Austria's radiotherapy equipment supply is 27% lower than the EU average and 34% lower than economic peers, while cancer cases are projected to increase by 25% between 2022 and 2040. The CyberKnife System's introduction aims to address this healthcare gap and provide more efficient cancer treatment options for Austrian patients.
Accuray reported its fiscal 2025 third quarter results, showing notable improvements in financial performance. The company achieved total net revenue of $113.2 million, marking a 12% increase year-over-year. The quarter saw reduced losses, with net loss decreasing to $1.3 million compared to $6.3 million in the prior year.
Key financial highlights include:
- Product revenue increased 16% to $57.3 million
- Service revenue grew 9% to $55.9 million
- Adjusted EBITDA improved to $6.0 million from $1.1 million
- Cash position strengthened to $78.8 million
Despite facing tariff challenges, the company maintained resilient performance. However, order backlog decreased 10% to $452.4 million. For fiscal year 2025, Accuray reaffirmed its adjusted EBITDA guidance of $28.5-31.0 million but adjusted revenue guidance to $452-460 million due to tariff impacts on product volume.
Accuray (NASDAQ: ARAY) has announced it will release its third quarter fiscal 2025 financial results on April 30, 2025. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on the same day to discuss the results for the quarter ended March 31, 2025.
Investors can access the conference call via USA dial-in (1-833-316-0563) or international dial-in (1-412-317-5747). A replay will be available for one week through 1-877-344-7529 (USA) or 1-412-317-0088 (international) using conference ID 8141169. Additionally, a live webcast will be accessible through the company's Investor Relations website at investors.accuray.com, with the replay available until Q4 FY2025 results announcement.
Accuray (NASDAQ: ARAY) presented new clinical data for its CyberKnife® System at the 2025 Radiosurgery Society Scientific Meeting, demonstrating its effectiveness in treating central nervous system tumors. Key findings include:
- A 25-year study showed 89.3% local control rate and 97.1% overall survival for vestibular schwannoma treatments
- Donut-shaped circumferential SBRT proved safe and effective for spinal metastases
- In elderly patients with trigeminal neuralgia, 90% experienced pain improvement or elimination
- For occipital condyle metastasis, the treatment achieved 93.8% local tumor control over three years, with 87.5% of patients experiencing pain relief
The CyberKnife System utilizes image guidance during treatment, leveraging up to 1,000 different beam angles and Synchrony® adaptive delivery technology to adjust for tumor or patient motion in real-time.